Published 1 year ago

FDA to review preventative option for RSV in infants, developers say

Summary by Ground News

The FDA has accepted a biologics license application for a long-acting antibody. If approved, it could be available for use in some infants and toddlers later this year. AstraZeneca and Sanofi, which developed the therapy, say the FDA "has indicated it will work to expedite its review"

0 Articles

All

Left

Center

Right

CNN

FDA to review preventative option for RSV in infants, developers say

The US Food and Drug Administration has accepted a biologics license application for a long-acting antibody for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus, according to the developers of the antibody. If approved, it could be available for use in some infants and toddlers later this year.

1 year ago·Atlanta, United States

Read Full Article

KRDO

FDA to review preventative option for RSV in infants, developers say

By Jacqueline Howard, CNN The US Food and Drug Administration has accepted a biologics license application for a long-acting antibody for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus, according to the developers of the antibody. If approved, it could be available for use in some infants and toddlers later this year. The pharmaceutical companies AstraZeneca and Sanofi, which developed the therapy …

1 year ago·Colorado Springs, United States

Read Full Article

WCVB

FDA to review preventative option for RSV in infants, developers say

An antibody, administered as a single dose, is the first-of-its-kind to offer some protection against RSV for all infants in their first year of life.

1 year ago·Boston, United States

Read Full Article

WLWT

FDA to review preventative option for RSV in infants, developers say

An antibody, administered as a single dose, is the first-of-its-kind to offer some protection against RSV for all infants in their first year of life.

1 year ago·Cincinnati, United States

Read Full Article

WLKY

FDA to review preventative option for RSV in infants, developers say

An antibody, administered as a single dose, is the first-of-its-kind to offer some protection against RSV for all infants in their first year of life.

1 year ago·Louisville, United States

Read Full Article

Koco News5

FDA to review preventative option for RSV in infants, developers say

An antibody, administered as a single dose, is the first-of-its-kind to offer some protection against RSV for all infants in their first year of life.

1 year ago·Sacramento, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.